Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$26.97 USD

26.97
2,911,983

-0.20 (-0.74%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $26.97 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Key Factors to Influence Penumbra's (PEN) Earnings in Q4

Penumbra (PEN) expects to gain from solid performance by neuro and peripheral vascular arms in Q4. Strong growth across all geographies is likely to drive the top line.

    What's in Store for Veeva Systems (VEEV) in Q4 Earnings?

    Consistent focus on Subscription Services is likely to drive Veeva Systems (VEEV) in Q4.

      Is a Beat in Store for Inogen (INGN) This Earnings Season?

      Strong product portfolio and a unique direct-to-consumer business model are expected to drive Inogen (INGN) in Q4.

        Will ACADIA (ACAD) Disappoint Investors in Q4 Earnings?

        ACADIA (ACAD) is expected to provide further update on the progress of Nuplazid when it reports Q4 results on Feb 27.

          What's in Store for Juno Therapeutics (JUNO) in Q4 Earnings?

          Although Juno Therapeutics' (JUNO) product portfolio lacks revenue figures, the company's most advanced pipeline candidates, JCAR017 and JCAR014, might still drive the stock in Q4.

            Can PBM Unit Drive Express Scripts' (ESRX) Earnings in Q4?

            Express Scripts (ESRX) expects Q4 results to show earnings growth on strength in PBM segment.

              What to Expect From BioMarin (BMRN) This Earnings Season?

              BioMarin (BMRN) is likely to see continued momentum in Kuvan sales in Q4. On the call, management is likely to comment on Brineura's launch progress and on the launch preparation for pegvaliase.

                What's in the Cards for Geron (GERN) This Earnings Season?

                With no approved product in Geron's (GERN) portfolio, investor focus is likely to remain on its sole pipeline candidate, imetelstat, in the Q4 release.

                  Novartis Psoriasis Drug Cosentyx Positive in SCALP Study

                  Novartis (NVS) announces positive results from the phase III study on multi-blockbuster drug Cosentyx for the treatment of moderate-to-severe scalp psoriasis.

                    What's in Store for Ligand (LGND) This Earnings Season?

                    Ligand's (LGND) Captisol formulation technology aids the company to form partnerships with several leading healthcare companies. This in turn might drive the stock in Q4.

                      AbbVie Presents New Data on Upadacitinib for Crohn's Disease

                      AbbVie (ABBV) announces new data from a phase II study on upadacitinib in adult patients with moderately to severely active Crohn's disease.

                        Celgene Reports Positive Data on Dermatology Drug Otezla

                        Celgene (CELG) is looking to expand dermatology drug Otezla's label and reported positive data from a late-stage study in patients with active Beh??et???s Disease.

                          Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat

                          Acorda (ACOR) misses on earnings in Q4 but beats on revenue estimates. The company's key drug Ampyra witnesses an increase in sales both year over year and sequentially.

                            Roche (RHHBY) to Acquire Flatiron Health for $1.9 Billion

                            Roche (RHHBY) announces that it will acquire Flatiron Health to accelerate development and delivery of breakthrough drugs for cancer patients.

                              Alkermes (ALKS) Beats Q4 Earnings, Revenue Estimates

                              Alkermes (ALKS) tops earnings and sales estimates in the fourth quarter of 2017 on the back of strong growth of Vivitrol and Aristada. The company provided a decent outlook for 2018.

                                Zoetis (ZTS) Beats on Q4 Earnings & Sales, Gives 2018 View

                                Zoetis' (ZTS) results exceed both earnings and sales expectations in the fourth quarter of 2017, making it the first animal health company to deliver more than $5 billion in revenues.

                                  Agios (AGIO) Q4 Loss Wider Than Expected, Revenues Slump Y/Y

                                  Agios (AGIO) reports wider-than-expected loss in the fourth quarter of 2017. Revenues fall short of expectations. The top line also declines year over year.

                                    Prothena's (PRTA) Loss Narrows in Q4, Pipeline Progresses

                                    Prothena (PRTA) reported a narrower-than-expected loss in the fourth quarter as the company continued with its pipeline progress.

                                      Shire (SHPG) Q4 Earnings Beat, Immunology Franchise Strong

                                      Shire (SHPG) reported better-than-expected fourth-quarter earnings and also registered strong growth in immunology franchise and newly launched products.

                                        Intercept (ICPT) Q4 Earnings & Sales Lag on Dull Ocaliva

                                        Intercept (ICPT) missed on both earnings and revenues in the fourth quarter as Ocaliva sales were drab due to safety issues of the drug.

                                          Roche's Rituxan Gets Priority Review for Label Expansion

                                          FDA accepts sBLA and grants priority review for Roche Group's (RHHBY) leukemia drug Rituxan.

                                            AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda

                                            AVEO Oncology (AVEO) is due to receive $2 million from its partner EUSA Pharma as the latter has been granted positive NICE recommendation for Fotivda (tivozanib).

                                              Exelixis Reports Positive Data From Thyroid Carcinoma Trial

                                              Exelixis (EXEl) announces positive data from a phase II trial of cabozantinib for the first-line treatment of metastatic radioiodine-refractory differentiated thyroid carcinoma.

                                                Catalyst Gets Positive FDA Advise on Firdapse NDA Refiling

                                                Catalyst (CPRX) posts positive results from a recent Type C meeting with the FDA on resubmitting the new drug application for Firdapse in treating Lambert-Eaton myasthenic syndrome.

                                                  Can CVG Boost Medtronic's (MDT) Q3 Earnings Once Again?

                                                  New therapies within CVG should help Medtronic???s (MDT) Q3 gain traction in the rapidly growing markets for LVAD, TAVR, drug-coated balloons, atrial fibrillation and insertable diagnostics.